Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the rationale for the Abi Race study looking at men with metastatic castration-resistant prostate cancer.
Daniel J. George, MD, professor of medicine and surgery, member, Duke Cancer Institute, discusses the rationale for the Abi Race study that looked at African-American patients and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC).
Background data suggested that African-American men were not only at higher risk for developing mCRPC, they were at much higher risk of dying from the disease, compared with Caucasian men. African-American men are 2.5 times more likely to die from mCRPC than Caucasian patients, and 5 times more likely than Asian-American men. Along with limited access to care and other important factors, researchers hypothesized that there must be a genetic difference between these patients. Furthermore, George says, African-American men are typically underrepresented in global clinical trials for mCRPC. In the COUGAR-302 study testing abiraterone acetate (Zytiga) only 2.6% of the patient cohort was African-American.
This small percentage of African-American patients had higher response rates and longer responses by prostate specific antigen, George says. These findings led to the Abi Race study.